Sean Van Helden, PharmD
@seanpharmd.bsky.social
Infectious Diseases Pharmacotherapy Fellow
Anti-Infective Research Laboratory
Anti-Infective Research Laboratory
Reposted by Sean Van Helden, PharmD
Check out the work from Dr. @seanpharmd.bsky.social & team on real-world experience of omadacycline for enterococcal infections at #ESCMIDGlobal 2025! 💊
Among hospitalized pts with enterococcal infections, omadacycline demonstrated high clinical success and low 30-day mortality (11%)!
Among hospitalized pts with enterococcal infections, omadacycline demonstrated high clinical success and low 30-day mortality (11%)!
April 13, 2025 at 8:40 AM
Check out the work from Dr. @seanpharmd.bsky.social & team on real-world experience of omadacycline for enterococcal infections at #ESCMIDGlobal 2025! 💊
Among hospitalized pts with enterococcal infections, omadacycline demonstrated high clinical success and low 30-day mortality (11%)!
Among hospitalized pts with enterococcal infections, omadacycline demonstrated high clinical success and low 30-day mortality (11%)!
Reposted by Sean Van Helden, PharmD
Don't miss Dr. @seanpharmd.bsky.social and colleagues as he shares two studies at #ESCMIDGlobal 2025 to highlight their findings on use of meropenem-vaborbactam among resistant pathogens and the role of Pseudomonas and biofilms.
April 15, 2025 at 7:30 AM
Don't miss Dr. @seanpharmd.bsky.social and colleagues as he shares two studies at #ESCMIDGlobal 2025 to highlight their findings on use of meropenem-vaborbactam among resistant pathogens and the role of Pseudomonas and biofilms.